Skin autofluorescence predicts cancer in subjects with type 2 diabetes

Autor: Anne-Claire Devouge, Laurence Baillet-Blanco, Claire Ducos, Kamel Mohammedi, Marine Rigo, Ninon Foussard, Marion Liebart, Quentin Battaglini, Marie Monlun, Maxime Lecocq, Alice Larroumet, Vincent Rigalleau, Pauline Poupon
Přispěvatelé: Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Admin, Oskar
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Blood Glucose
Glycation End Products
Advanced
Male
medicine.medical_specialty
Endocrinology
Diabetes and Metabolism
030209 endocrinology & metabolism
[SDV.CAN]Life Sciences [q-bio]/Cancer
Type 2 diabetes
Gastroenterology
Diseases of the endocrine glands. Clinical endocrinology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
[SDV.CAN] Life Sciences [q-bio]/Cancer
Internal medicine
Diabetes mellitus
Neoplasms
Cancer screening
medicine
Humans
10. No inequality
Pathophysiology/Complications
Skin
Cancer
2. Zero hunger
[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism
Proportional hazards model
business.industry
Absolute risk reduction
[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism
medicine.disease
RC648-665
3. Good health
chemistry
Diabetes Mellitus
Type 2
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
030220 oncology & carcinogenesis
Advanced glycation end-product
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Advanced glycation end product
business
Body mass index
Biomarkers
Zdroj: BMJ Open Diabetes Research & Care
BMJ Open Diabetes Research & Care, BMJ Journals, 2021, 9 (1), pp.e001312. ⟨10.1136/bmjdrc-2020-001312⟩
BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)
ISSN: 2052-4897
Popis: IntroductionSubjects with type 2 diabetes have an excess risk of cancer. The potential role of advanced glycation end products (AGEs) accumulated during long-term hyperglycemia in cancer development has been suggested by biological studies but clinical data are missing. AGEs can be estimated by measuring the skin autofluorescence. We searched whether the skin autofluorescence could predict new cancers in persons with type 2 diabetes.Research design and methodsFrom 2009 to 2015, we measured the skin autofluorescence of 413 subjects hospitalized for uncontrolled or complicated type 2 diabetes, without any history of cancer. The participants were followed for at least 1 year and the occurrences of new cancers were compared according to their initial skin autofluorescences.ResultsThe participants were mainly men (57.9%), with poorly controlled (HbA1c 72±14 mmol/mol or 8.7%±1.8%) and/or complicated type 2 diabetes. Their median skin autofluorescence was 2.6 (2.2–3.0) arbitrary units. Forty-five new cancer cases (10.9%) were registered during 4.8±2.3 years of follow-up: 75.6% of these subjects had skin autofluorescence higher than the median (χ2: p=0.001). By Cox regression analysis adjusted for age, gender, body mass index, history of smoking and renal parameters, skin autofluorescence >2.6 predicted a 2.57-fold higher risk of cancer (95% CI 1.28 to 5.19, p=0.008). This association remained significant after excluding the eight cancers that occurred in the 4 years after inclusion (OR 2.95, 95% CI 1.36 to 6.38, p=0.006). As a continuous variable, skin autofluorescence was also related to new cancers (OR 1.05, 95% CI 1.01 to 1.10, p=0.045).ConclusionsSkin autofluorescence, a potential marker of glycemic memory, predicts the occurrence of cancer in subjects with type 2 diabetes. This relation provides a new clinical argument for the role of AGEs in cancer. Their estimation by measuring the skin autofluorescence may help select subjects with diabetes in cancer screening programs.
Databáze: OpenAIRE
Externí odkaz: